Taking our results into account as a whole, the synergistic effect of CXCL12 and collagen mediated, at least in part, via the p38 MAPK pathway might be one of therapeutic targets for the prevention of atheroprogression and thromboembolic disease in patients strongly expressing CXCL12. The gene discussed is CXCL12; the disease is Thromboembolism.